Amendments to the Claims

Please cancel Claims 4-31, 34, 53, 54, 55 and 58. Please amend Claims 1, 32, 33, and 56. Please add new Claims 59-61. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A compound comprising a target specific portion and an effector portion wherein:

(i) the target specific portion comprises a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the binding specificity for oncofoetal fibronectin of the parent monoclonal antibody; and

(ii) the effector portion comprises interleukin-12, or a functional fragment or variant thereof;

wherein the target specific portion is capable of binding an amino acid sequence within the repeat 7 domain of fibronectin,

wherein the compound comprises one or more polypeptides selected from the group consisting of the polypeptide of SEQ ID NO: 6 and the polypeptide of SEQ ID NO: 7, and wherein

SEQ ID NO: 6 includes SEQ ID NO: 1 and SEQ ID NO: 3; and

SEQ ID NO: 7 includes SEQ ID NO: 2.

2-31. (Cancelled)

32. (Currently Amended) A compound according to Claim [[30]] 1 wherein the compound comprises the polypeptide of SEQ ID NO:6 and the polypeptide of SEQ ID NO:7.

33. (Currently Amended) A compound according to Claim [[30]] 1 further comprising the polypeptide of SEQ ID NO:4 linked by at least one disulphide bond to the polypeptide of SEQ ID NO:6.

34-42. (Cancelled)

43. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

44. (Original) A pharmaceutical composition according to Claim 43 wherein the composition is suitable for parenteral administration.

45-46. (Cancelled)

47. (Withdrawn) A method of treating a patient with cancer, the method comprising administering a compound according to Claim 1 to said patient.

48. (Withdrawn) The method according to Claim 47 wherein the mammal is a human.

49. (Withdrawn) The method according to Claim 47 wherein the patient has a solid tumor.

50. (Withdrawn) The method according to Claim 47 wherein the cancer is a glioblastoma.

51-55. (Cancelled)

56. (Currently Amended) A compound according to Claim 1, ~~wherein:~~
~~the target specific portion comprises~~ , wherein the compound comprises the polypeptide of SEQ ID NO: 6, and further wherein:

~~the polypeptide of SEQ ID NO: 1; and~~

the target specific portion further includes the polypeptide of SEQ ID NO: 2; and

~~the effector portion comprises:~~

~~the polypeptide of SEQ ID NO: 3; and~~

the effector portion further includes the polypeptide of SEQ ID NO: 4 conjugated to SEQ ID NO: 3 by at least one disulphide bond;

and wherein the target specific portion is fused to the effector portion via the linker sequence that comprises the amino acid sequence ATATPGAA (SEQ ID NO: 5).

57. (Previously Presented) A compound according to Claim 1, comprising:

the polypeptide of SEQ ID NO: 6;

the polypeptide of SEQ ID NO: 7 conjugated to the polypeptide SEQ ID NO: 6 by at least one disulphide bond; and

the polypeptide of SEQ ID NO: 4 conjugated to the polypeptide SEQ ID NO: 6 by a disulphide bond.

58. (Cancelled)

59. (New) A compound comprising a target specific portion and an effector portion wherein:

(i) the target specific portion comprises a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the binding specificity for oncofoetal fibronectin of the parent monoclonal antibody; and

(ii) the effector portion comprises interleukin-12, or a functional fragment or variant thereof;

wherein the target specific portion is capable of binding an amino acid sequence within the repeat 7 domain of fibronectin, wherein:

the target specific portion comprises:

the polypeptide of SEQ ID NO: 1; and;

the polypeptide of SEQ ID NO: 2; and

the effector portion comprises:

an IL12p35 domain; and

an IL12p40 domain conjugated to the IL12p35 domain by at least one disulphide bond;

and wherein the target specific portion is fused to the effector portion via the linker sequence that comprises the amino acid sequence ATATPGAA (SEQ ID NO: 5).

60. (New) The compound of Claim 59, wherein the compound comprises a polypeptide selected from the group consisting of the polypeptide of SEQ ID NO: 6 and the polypeptide of SEQ ID NO: 7.

61. (New) The compound of Claim 1, wherein the compound comprises the polypeptide of SEQ ID NO: 7, and further wherein:

the target specific portion further includes includes:

the polypeptide of SEQ ID NO: 1; and

the effector portion comprises:

the polypeptide of SEQ ID NO: 3; and

the polypeptide of SEQ ID NO: 4 conjugated to SEQ ID NO: 3 by at least one disulphide bond;

and wherein the target specific portion is fused to the effector portion via the linker sequence that comprises the amino acid sequence ATATPGAA (SEQ ID NO: 5).